COVID-19 vaccine safety and effectiveness at 3 months in institutionalized old people.

ABSTRACT:

Background

Older age and associated comorbid conditions increase the risk of severe form of COVID-19 and death. The SARS-CoV-2 vaccination campaign began in France in December 2020 targeting institutionalized older population before having been evaluated in this population. The objective of our study was to assess the tolerability of vaccination 21 days (D21) and 90 days after the first vaccination (D90) in institutionalized old people. Secondary objective was to assess its effectiveness (mortality, hospitalization and occurrence of COVID) at D21 and D90.

Methods

People living in nursing homes or in long-term hospitalization facilities in France were included 12-2020-06-2021. They were divided into SARS-CoV-2 vaccinated and unvaccinated groups. Vaccine tolerability was prosp

SUBMITTER: Malignac M 

PROVIDER: S-EPMC11664901 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature